Generic Brexafemme Availability
Last updated on Apr 10, 2025.
Brexafemme is a brand name of ibrexafungerp, approved by the FDA in the following formulation(s):
BREXAFEMME (ibrexafungerp citrate - tablet;oral)
-
Manufacturer: SCYNEXIS
Approval date: June 1, 2021
Strength(s): EQ 150MG BASE [RLD]
Is there a generic version of Brexafemme available?
No. There is currently no therapeutically equivalent version of Brexafemme available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brexafemme. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Salts and polymorphs of SCY-078
Patent 10,174,074
Issued: January 8, 2019
Inventor(s): Zhang Yi
Assignee(s): SCYNEXIS, INC.SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.
Patent expiration dates:
- January 19, 2035✓✓
- January 19, 2035
-
Salts and polymorphs of SCY-078
Patent 10,370,406
Issued: August 6, 2019
Inventor(s): Zhang Yi
Assignee(s): SCYNEXIS, INC.SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.
Patent expiration dates:
- January 19, 2035✓
- January 19, 2035
-
Salts and polymorphs of SCY-078
Patent 10,927,142
Issued: February 23, 2021
Inventor(s): Zhang Yi
Assignee(s): SCYNEXIS, INC.SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.
Patent expiration dates:
- January 19, 2035✓
- January 19, 2035
-
Antifungal agents with enhanced activity in acidic pH
Patent 11,534,433
Issued: December 27, 2022
Inventor(s): Angulo Gonzalez; David A.
Assignee(s): Scynexis, Inc. (Jersey City, NJ)Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.
Patent expiration dates:
- June 10, 2039✓
- June 10, 2039✓
- June 10, 2039
-
Antifungal agents
Patent 8,188,085
Issued: May 29, 2012
Inventor(s): Greenlee; Mark L. et al.
Assignee(s): Merck Sharp & Dohme Corp. (Rahway, NC); Seynexis, Inc. (Research Triangle Park, NC)Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-.beta.-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
Patent expiration dates:
- August 28, 2030✓✓✓
- August 28, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 30, 2025 - REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
- June 1, 2026 - NEW CHEMICAL ENTITY
- June 1, 2031 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Brexafemme (ibrexafungerp)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antifungals
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
